OncoAssure Ltd, an Irish medical diagnostics company headquartered at NovaUCD in Dublin, today announced an exclusive partnership with Illinois-based GoPath Diagnostics. Under this agreement, GoPath, a leading full-service CAP-accredited and CLIA-certified anatomic, molecular, and digital pathology company, will hold the exclusive rights to provide the OncoAssureTM Prostate test throughout the United States.
OncoAssureTM Prostate is a next-generation clinically validated prognostic test designed to support clinical decision-making for men diagnosed with localized prostate cancer. By integrating advanced genomic data with well-validated clinical variables, the test empowers physicians and patients to make personalized, data-driven treatment decisions at two critical points in the prostate cancer pathway, post-biopsy and post-surgery.
Clinical Validation1,2 of OncoAssureTM Prostate demonstrates how it improves risk stratification over standard clinical and pathological information, optimizing patient management after diagnosis.
Patients with a higher OncoAssureTM Prostate result were 4.4 times more likely to experience biochemical recurrence within five years compared to patients with a lower result. Separately, patients with a higher test result were 9.7 times more likely to experience adverse pathology, associated with more aggressive cancer, compared to patients with a lower result.
This collaboration leverages GoPath's extensive resources in the Urological field and its national sales infrastructure to meet the growing demand for validated prognostic testing in the US urology segment.
“Partnering with GoPath represents an important step in expanding access to OncoAssureTM Prostate in the United States. By combining our focus on clinically meaningful biomarker development with GoPath’s proven capabilities in delivering high-quality diagnostic services, we can better support clinicians with actionable insights at key decision points in prostate cancer management,” said, Des O’Leary, CEO, OncoAssure Ltd.
“Partnering with OncoAssure allows us to expand our prostate cancer portfolio from morphologic and molecular diagnosis, targeted immunotherapies, and germline testing, to now include a clinically validated prognostic test, OncoAssureTM Prostate, for prostate cancer patients, which is a very significant step forward. By combining OncoAssure’s genomic innovation with our national sales infrastructure, we are better positioned to support urologists with actionable insights across key decision points in the patient journey,” said, Dr Jim Lu, CEO and Medical Director, GoPath Diagnostics.
